

Exploring ustekinumab therapy for paediatric ulcerative colitis:

a multi-centre prospective study

OUR AIM was to evaluate the effectiveness of ustekinumab for treating ulcerative colitis (UC) in children.

BACKGROUND - a previous trial demonstrated effectiveness of ustekinumab in adults with UC (even after prior biologic failure), but no pediatric data is available to date.

Primary Outcomes

11 of 25 (44%) of children met the goal of steroid-free clinical remission after 52 weeks of ustekinumab.

STUDY POPULATION

- 25 children across Canada who had inadequate response to other biologics.
- Children were followed for 52 weeks after starting ustekinumab.

DEFINITIONS

Ulcerative Colitis (UC) is a type of inflammatory bowel disease (IBD) with inflammation in the large intestine.

Ustekinumab, anti-TNF and vedolizumab are biologic therapies that target different parts of the immune system in treating IBD.

Steroid-free clinical remission is when a person has no symptoms of UC (ie, normal bowel movements, no abdominal pain, and no limitation in activity) and is not receiving any steroid treatment.

Endoscopic Improvement is improvement in severity of inflammation as evaluated by colonoscopy.

